 Biogen stock toppled Monday after a report suggested its experimental Alzheimers treatment caused a patients fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimers Death While Axsome Soars On Its Study Success appeared first on Investors Business Daily. 